ArticleJournal of contemporary brachytherapy2022
High-dose-rate skin brachytherapy with interstitial, surface, or a combination of interstitial and surface mold technique.
Article in Journal of contemporary brachytherapy, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
9 citing papers in PubMed, 7 citations in OpenAlex.
- "Clinical outcomes of definitive interstitial/hybrid high-dose-rate and pulsed-dose-rate interventional radiotherapy (brachytherapy) for non-melanoma skin cancer: A single-center retrospective analysis".Clinical and translational radiation oncology · 2027Article
- Computed tomography-based customized surface mould high-dose-rate brachytherapy for non-melanoma skin cancer of the scalp and face. Long-term results: Optimizing for reduction of late toxicity and improving cosmetic outcome.Journal of contemporary brachytherapy · 2026Article
- Cylindrical silicone applicator for superficial brachytherapy of the finger: Design and manufacturing.Journal of contemporary brachytherapy · 2025Article
- Radiotherapeutic Modalities and Advancements in the Treatment of Cutaneous Malignancies.Journal of clinical medicine · 2025Review
- High-dose-rate surface mold with tumor translucency brachytherapy for a 103-year-old patient with skin cancer, dementia, tremor, and kyphosis: a case report.Nagoya journal of medical science · 2025Article
- Surface mold brachytherapy for head and neck non-melanoma skin cancer - local control rates and survival: A retrospective analysis.Journal of contemporary brachytherapy · 2024Article
- Comparison of image registration methods in patients with non-melanoma skin cancer treated with superficial brachytherapy.Physics and imaging in radiation oncology · 2024Article
- Multilayer intensity modulated contact interventional radiotherapy (brachytherapy): Stretching the therapeutic window in skin cancer.Journal of contemporary brachytherapy · 2023Article
- ORIFICE (Interventional Radiotherapy for Face Aesthetic Preservation) Study: Results of Interdisciplinary Assessment of Interstitial Interventional Radiotherapy (Brachytherapy) for Periorificial Face Cancer.Journal of personalized medicine · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: In order to demonstrate capabilities of brachytherapy in skin cancer treatment, we reviewed clinical outcomes of patients with non-melanoma skin cancer (NMSC) treated with high-dose-rate brachytherapy (HDR-BT) at a single-institution. Material and methods: A surface custom mold (SC), interstitial (IS), or a combination of IS and SC applicator (IS + SC) was used for treatment based on depth of tumor invasion. Contoured growth tumor volume plus a 0.5 cm margin for basal cell carcinomas (BCC) and a 1-1.5 cm margin for squamous cell carcinomas (SCC) was considered a target. A prescription dose of 41.6 Gy in 8 fractions was delivered to BCC, and 46.8 Gy in 9 fractions to SCC. Results: From 2013 to 2018, a total of 751 NMSC patients (534 BCCs and 217 SCCs) were treated with HDR-BT (518 with IS, 225 with SC, and 8 with IS + SC technique). Thirty patients (4%) partially responded to treatment, and 721 patients (96%) had complete responses. Only 3 patients (0.4%) displayed local recurrences. Grade 1, 2, and 3 acute toxicities were observed in 28.0%, 46.7%, and 1.2% of patients, respectively. Grade 1, 2, and 3 late toxicities were observed in 3.3%, 1.3%, and 0.1% of cases. Cosmetic results were excellent in 79.9%, good in 17.8%, fair in 1.7%, and poor in 0.5% of patients. Conclusions: HDR-BT using SC, IS, or IS + SC is an effective treatment for NMSC with good outcomes and cosmetic results in both BCC and SCC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.